HEALTHJul 8 · 22:46 UTCSEMAFORTom Chivers

GLP-1 use reaches new high in US

The use of GLP-1 drugs like Wegovy for weight loss in the US has increased from 3% to 11% in 2024, with an additional 4% reporting past use, per Gallup polling. Obesity rates in the US fell to 36.4% in 2024 from a peak of 39.9% in 2022, and early research suggests these drugs may offer benefits beyond weight loss, including treating alcohol abuse and reducing coronary disease risk.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

GLP-1 drugstopicWegovytopicGalluporganizationobesity ratestopicalcohol abusetopiccoronary disease risktopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 20 · 02:46 UTC
Research shows weight-loss drugs may also reduce cancer risk
HEALTHMay 12 · 14:00 UTC
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
HEALTHMay 31 · 15:56 UTC
What Ozempic is actually doing to obesity rates in the US
HEALTHApr 30 · 22:45 UTC
Active ingredient in Ozempic shows early promise for treating alcohol use disorder